Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results

Go back to Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results

Alder Biopharm (ALDR) PT Lowered to $24 at RBC Capital

May 9, 2018 8:12 AM EDT

RBC Capital lowered its price target on Alder Biopharm (NASDAQ: ALDR) to $24.00 (from $26.00) while maintaining a Outperform rating.

... More